Results 151 to 160 of about 24,362 (263)
The impact of prompt diagnosis and treatment, and early predictors of outcome severity in this cohort. Abstract Objective Most therapies for drug‐resistant epilepsy (DRE) focus on focal‐onset seizures, the most common seizure types. Studying primary generalized tonic–clonic seizures (PGTCS) is more challenging due to diagnostic and recruitment ...
Katherine Eggleston +6 more
wiley +1 more source
Abstract Objective To evaluate the risk of hypersensitivity reactions, including dermatological rashes, when cenobamate (CNB) is restarted at maintenance doses after temporary discontinuation. Methods We leveraged the natural experiment of long antiseizure medication discontinuation during intracranial EEG evaluation and conducted a retrospective ...
Marina Feldman +4 more
wiley +1 more source
Abstract Non‐seizure issues (NSIs), including cognition, behavior/psychiatric symptoms, adaptive and social functioning, sleep, autonomic, and motor impairments, often shape day‐to‐day outcomes in Lennox–Gastaut syndrome (LGS) more than seizures, yet clinicians lack LGS‐specific, feasible assessment pathways.
Giancarlo Di Gennaro +7 more
wiley +1 more source
Abstract Objective To evaluate the occurrence, clinical correlates, and screening accuracy of depressive symptoms (DS) among adults with epilepsy in Georgia, a country with limited mental health resources. Methods We conducted a cross‐sectional study in adults with epilepsy attending a tertiary care center. We assessed DS using two validated tools: the
Ketevan Silagadze +5 more
wiley +1 more source
Abstract Objective To evaluate the real‐world effectiveness, safety, and treatment retention of cenobamate (CNB) in patients with drug‐resistant epilepsy (DRE), including ultra‐refractory epilepsy (URE), high seizure burden, and extensive prior treatment history.
Ondřej Strýček +9 more
wiley +1 more source
Abstract Pediatric drug‐resistant epilepsy (DRE) remains a significant clinical challenge, with few effective pharmacological options. This European multicenter retrospective study assessed the real‐world efficacy, tolerability, and retention of off‐label cenobamate (CNB) in 108 children and adolescents with DRE (median age: 13.83 years, range 3.9–19.8)
Konstantin L. Makridis +14 more
wiley +1 more source
Abstract Objective Neurodevelopmental disorders (NDDs) and epilepsy are often associated. Increasing evidence highlights a pivotal role for pathogenic variants in genes encoding synaptic scaffolding proteins. Within this group, TANC2 has recently been implicated in intellectual developmental disorder with autistic features and language delay, with or ...
Lorenzo Perilli +12 more
wiley +1 more source
Comprehensive insights into the prescribing trends of carbamazepine, lamotrigine, lithium, and valproate in the UK Primary Care from 1995 to 2018. [PDF]
Samsuddin SW +3 more
europepmc +1 more source
Cost-effectiveness of add-on lamotrigine therapy in clinical pratice
OBJECTIVE: This retrospective study addresses the cost-effectiveness of add-on therapy with lamotrigine in clinical practice. METHODS: Two years' observational data of 165 patients were used.
Severens, J.L. +11 more
core
Polypharmacy among adolescents and adults with cerebral palsy in a clinical setting
Abstract Background Adolescents and adults with cerebral palsy often experience multimorbidity related to their condition, which primarily affects movement and posture but is also associated with pain, epilepsy, mood disorders, and other conditions. As such, these patients are often prescribed a range of medications to manage symptoms, thereby putting ...
Caitlin Cassidy +3 more
wiley +1 more source

